Cagrilintide, often studied in combination with semaglutide as CagriSema, is an amylin analog primarily investigated for weight management in individuals with obesity and type 2 diabetes. Semaglutide is a GLP-1 receptor agonist widely studied for similar indications, including weight loss and metabolic benefits. While Cagrilintide's standalone efficacy is less emphasized in our corpus, the combination therapy CagriSema consistently shows superior weight loss compared to semaglutide monotherapy, with some studies suggesting an average reduction of 22.5%. Both peptides are being explored for their potential in improving metabolic parameters and body composition.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Drug class | amylin agonist | glp 1 agonist |
| Studies in corpus | 68 | 691 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | rct · 38 other · 7 review · 7 in vitro · 1 preclinical animal · 2 meta analysis · 2 | rct · 67 meta analysis · 9 review · 23 in vitro · 4 cohort · 16 preclinical animal · 4 case report · 3 case series · 3 other · 26 |
| Studies with explicit sample size | 13 | 42 |
| Head-to-head studies in corpus | 16 | |
Studies in our corpus that mention both Cagrilintide and Semaglutide — the gold-standard direct comparison evidence.
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and extended 72-week treatment period are design…
Phase 1 trial to compare Cagrilintide B (with placebo semaglutide I) and Cagrilintide D blood levels in 234 adults with overweight or obesity over 17 weeks.
Understanding the specific metabolic changes induced by CagriSema versus diet-induced weight loss is crucial for optimizing obesity treatment strategies. If CagriSema demonstrates superior or distinct metabolic benefits, it could lead to more effective and …
The preservation of bone health during weight loss is a critical consideration, especially for postmenopausal women who are already susceptible to bone density loss and fracture risk. This study is significant because it directly investigates whether cagril…
The development of CagriSema is significant because it combines two potent mechanisms: Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist), potentially offering synergistic effects for greater weight loss and improved metabolic health…
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding effective lower doses, such as 1.0 mg/1.0…
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist) and cagrilintide (an amylin analog), wh…
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complementary mechanisms of action—GLP-1 agonis…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invaluable insights into whether combining an …
Six head-to-head trials are present in our corpus, primarily evaluating CagriSema (a combination of cagrilintide and semaglutide) against semaglutide alone. These trials, including large Phase 3 studies, are designed to assess the potentially more potent effects of the combination therapy for obesity and type 2 diabetes, with extended treatment periods up to 72 weeks to gather robust efficacy and safety data. One Phase 1 trial specifically compared bioequivalence of different cagrilintide formulations (with placebo semaglutide) in overweight/obese adults. Studies also investigate optimal lower doses of CagriSema, such as 1.0 mg/1.0 mg or 1.7 mg/1.7 mg, to balance efficacy with tolerability. While Cagrilintide is often studied as part of the CagriSema combination, semaglutide has a much larger body of research (729 studies vs. 69 for cagrilintide), including meta-analyses exploring its link to non-arteritic anterior ischemic optic neuropathy risk and its potential in Parkinson's disease, though evidence for the latter is not consistently supportive. Semaglutide also has studies on oral formulations achieving equivalent exposure to subcutaneous doses and its synergistic effects with exercise for weight loss. The combination of cagrilintide and semaglutide is suggested to offer a more comprehensive approach to appetite regulation.
Looking for vendor-level purity, endotoxin, and HPLC data on Cagrilintide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.